Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy

World Journal of Gastroenterology

Volumn 19, Issue 12, 2013, Pages 1861-1876

  Wallace, John L ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti inflammatory; Aspirin; Bacteria; Bile; Bleeding; Enterohepatic; Hemorrhage; Hydrogen sulfide; Intestinal; Non steroidal; Prostaglandin; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; ATB 346; BILE ACID; CALGRANULIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LACTOFERRIN; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; MOSAPRIDE; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ONDANSETRON; PHOSPHATIDYLCHOLINE; PLACEBO; PROBIOTIC AGENT; PRODRUG; PROSTAGLANDIN; RAMOSETRON; REBAMIPIDE; ROFECOXIB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; CAPSULE ENDOSCOPY; DIGESTIVE SYSTEM INJURY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ENTEROHEPATIC CIRCULATION; ENTEROPATHY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE BACTERIUM; HUMAN; INFLAMMATION; INTESTINAL BLEEDING; INTESTINE INJURY; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; POLYPHARMACY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; ULCER;

EID: 84875621014     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i12.1861     Document Type: Article

References (182)

1. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88: 1547-1565 [PMID: 18923189 DOI: 10.1152/ physrev.00004.2008]
2. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006; 82: 186-191 [PMID: 16517800 DOI: 10.1136/pgmj.2005.039586]
3. McCarthy DM. GI bleeding: problems that persist. Gastrointest Endosc 2009; 70: 225-228 [PMID: 19631801 DOI: 10.1016/ j.gie.2008.12.247]
4. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847 [PMID: 8500743]
5. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59 [PMID: 15645405 DOI: 10.1016/S1542-3565(04)00603-2]
6. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol 2011; 17: 4647-4653 [PMID: 22180706 DOI: 10.3748/wjg.v17.i42.4647]
7. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 2012; 165: 67-74 [PMID: 21627632 DOI: 10.1111/j.1476-5381.2011.01509.x]
8. Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci 1999; 2: 5-14 [PMID: 10951657]
9. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-869 [PMID: 1499936]
10. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506 [PMID: 11876703 DOI: 10.1046/ j.1365-2036.2002.01197.x]
11. Endo H, Sakai E, Higurashi T, Yamada E, Ohkubo H, Iida H, Koide T, Yoneda M, Abe Y, Inamori M, Hosono K, Takahashi H, Kubota K, Nakajima A. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44: 833-838 [PMID: 22749649 DOI: 10.1016/j.dld.2012.05.016]
12. Casado Arroyo R, Polo-Tomas M, Roncalés MP, Scheiman J, Lanas A. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: longterm follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012; 98: 718-723 [PMID: 22523056 DOI: 10.1136/heartjnl-2012-301632]
13. Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol 2012; 18: 3167-3172 [PMID: 22791953 DOI: 10.3748/wjg.v18. i24.3167]
14. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528 [PMID: 11087881 DOI: 10.1056/ NEJM200011233432103]
15. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255 [PMID: 10979111]
16. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci 1999; 20: 4-6 [PMID: 10101953 DOI: 10.1016/S0165-6147(98)01283-8]
17. Graham DY, Jewell NP, Chan FK. Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Am J Med Sci 2011; 342: 356-364 [PMID: 21986300 DOI: 10.1097/ MAJ.0b013e3182113658]
18. Bjarnason I, Price AB, Zanelli G, Smethurst P, Burke M, Gumpel JM, Levi AJ. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology 1988; 94: 1070-1074 [PMID: 3345876]
19. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179 [PMID: 20638563 DOI: 10.1016/S0140-6736(10)60673-3]
20. Sutherland LR, Verhoef M, Wallace JL, Van Rosendaal G, Crutcher R, Meddings JB. A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet 1994; 343: 998-1000 [PMID: 7909091 DOI: 10.1016/ S0140-6736(94)90125-2]
21. Bjarnason I, Peters TJ. Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview. Gut 1989; 30 Spec No: 22-28 [PMID: 2691345 DOI: 10.1136/gut.30.Spec_No.22]
22. Bjarnason I, Smethurst P, Clark P, Menzies I, Levi J, Peters T. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol Suppl 1989; 164: 97-102; discussion 102-103 [PMID: 2510288 DOI: 10.3109/00365528909091195]
23. Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 201-206 [PMID: 10974182 DOI: 10.1016/S0002-9343(00)00470-8]
24. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-1208 [PMID: 1427372 DOI: 10.1136/gut.33.9.1204]
25. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178 [PMID: 15887101 DOI: 10.1053/ j.gastro.2005.03.020]
26. Endo H, Hosono K, Inamori M, Kato S, Nozaki Y, Yoneda K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Abe Y, Kirikoshi H, Kobayashi N, Kubota K, Saito S, Matsuhashi N, Nakajima A. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44-51 [PMID: 19246922 DOI: 10.1159/000204465]
27. Solomon DH, Gurwitz JH. Toxicity of nonsteroidal antiinflammatory drugs in the elderly: is advanced age a risk factor? Am J Med 1997; 102: 208-215 [PMID: 9217572 DOI: 10.1016/S0002-9343(96)00380-4]
28. Hernández-Díaz S, Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157-163 [PMID: 11809354 DOI: 10.1016/ S0895-4356(01)00461-9]
29. Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, Stolte M, Talley NJ, Agréus L. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006; 163: 1025-1034 [PMID: 16554343 DOI: 10.1093/aje/ kwj129]
30. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308 [PMID: 16740558 DOI: 10.1136/bmj.332.7553.1302]
31. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402 [PMID: 15300570 DOI: 10.1053/ j.gastro.2004.05.001]
32. Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288 [PMID: 12039807 DOI: 10.1136/bmj.324.7349.1287]
33. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674 [PMID: 15325831 DOI: 10.1016/S0140-6736(04)16893-1]
34. Sostek MB, Fort JG, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 2011; 27: 847-854 [PMID: 21319944 DOI: 10.1185/03007995.2011.555756]
35. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016 [PMID: 9041264 DOI: 10.1053/ gast.1997.v112.pm9041264]
36. Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006; 73 Suppl 1: 136-150 [PMID: 16498262 DOI: 10.1159/000089789]
37. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322, 1322. e1-5 [PMID: 21745447 DOI: 10.1053/j.gastro.2011.06.075]
38. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010; 159: 1236-1246 [PMID: 20128814 DOI: 10.1111/j.1476-5381.2009.00611.x]
39. Satoh H, Amagase K, Takeuchi K. Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 2012; 343: 270-277 [PMID: 22854201 DOI: 10.1124/jpet.112.197475]
40. Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, Idström JP, Cederberg C, Blum AL, Fried M. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 1994; 35: 455-460 [PMID: 8174980 DOI: 10.1136/gut.35.4.455]
41. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23: 3-10 [PMID: 16393275 DOI: 10.1111/ j.1365-2036.2006.02707.x]
42. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-508 [PMID: 20060064 DOI: 10.1016/j.cgh.2009.12.022]
43. Daniell HW. NSAID-PPI enteropathy in humans. Gastroenterology 2012; 142: e20; author reply e20-e21 [PMID: 22374457 DOI: 10.1053/j.gastro.2012.02.004]
44. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41: 380-386 [PMID: 21128930 DOI: 10.1111/ j.1365-2362.2010.02419.x]
45. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003; 15: 573-574; author reply 574 [PMID: 12702920]
46. Andréasson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 2011; 270: 50-57 [PMID: 21205026 DOI: 10.1111/j.1365-2796.2010.02340.x]
47. Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gastroenterol 2009; 43: 551-553 [PMID: 19142168 DOI: 10.1097/ MCG.0b013e31817d3fa1]
48. Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a casecontrol study. Aliment Pharmacol Ther 2010; 32: 1124-1128 [PMID: 21039674 DOI: 10.1111/j.1365-2036.2010.04453.x]
49. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology 2011; 140: 1155-1165 [PMID: 21303675 DOI: 10.1053/ j.gastro.2011.02.003]
50. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141 [PMID: 15704047 DOI: 10.1016/S1542-3565(04)00619-6]
51. Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, McAlindon M, Fortun P, Schumann S, Bolten W, Shonde A, Hugot JL, Yu V, Arulmani U, Krammer G, Rebuli R, Toth E. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6: 536-544 [PMID: 18242145 DOI: 10.1016/j.cgh.2007.12.023]
52. Reuter BK, Davies NM, Wallace JL. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-117 [PMID: 8978349 DOI: 10.1016/ S0016-5085(97)70225-7]
53. Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 520 [PMID: 1671893]
54. Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 2010; 40: 504-510 [PMID: 20412292 DOI: 10.1111/ j.1365-2362.2010.02290.x]
55. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410-411 [PMID: 4564318 DOI: 10.1038/240410a0]
56. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-2696 [PMID: 1849272 DOI: 10.1073/pnas.88.7.2692]
57. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872 [PMID: 1712772]
58. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol 2005; 145: 275-282 [PMID: 15778736 DOI: 10.1038/ sj.bjp.0706201]
59. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-1923 [PMID: 12055598 DOI: 10.1053/gast.2002.33647]
60. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-109 [PMID: 9649464 DOI: 10.1016/S0016-5085(98)70370-1]
61. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698-701 [PMID: 10371510]
62. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAIDinduced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-714 [PMID: 10982765 DOI: 10.1053/gast.2000.16510]
63. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002; 300: 754-761 [PMID: 11861778 DOI: 10.1124/jpet.300.3.754]
64. Serhan CN, Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 2001; 107: 1481-1489 [PMID: 11413151 DOI: 10.1172/ JCI13375]
65. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21: 325-332 [PMID: 17267386 DOI: 10.1096/fj.06-7227rev]
66. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-397 [PMID: 9024292 DOI: 10.1053/gast.1997. v112.pm9024292]
67. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 2002; 99: 13243-13247 [PMID: 12232050 DOI: 10.1073/pnas.202392199]
68. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795-804 [PMID: 9535006 DOI: 10.1038/sj.bjp.0701672]
69. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 2007; 52: 2095-2103 [PMID: 17429720 DOI: 10.1007/s10620-006-9597-z]
70. Davies NM, Sharkey KA, Asfaha S, Macnaughton WK, Wallace JL. Aspirin causes rapid up-regulation of cyclooxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 1997; 11: 1101-1108 [PMID: 9663836 DOI: 10.1046/ j.1365-2036.1997.00247.x]
71. Fiorucci S, de Lima OM, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, Wallace JL. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002; 123: 1598-1606 [PMID: 12404234 DOI: 10.1053/ gast.2002.36558]
72. Souza MH, de Lima OM, Zamuner SR, Fiorucci S, Wallace JL. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol 2003; 285: G54-G61 [PMID: 12637254]
73. Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040-1045 [PMID: 17625980 DOI: 10.1016/j.cgh.2007.04.031]
74. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423 [PMID: 10581086]
75. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-353 [PMID: 9378390 DOI: 10.1136/gut.41.3.344]
76. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970; 58: 772-780 [PMID: 5423889]
77. Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 2007; 81: 291-298 [PMID: 17151867 DOI: 10.1007/s00204-006-0149-2]
78. Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol 2011; 62: 491-496 [PMID: 22100851]
79. Seitz S, Boelsterli UA. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998; 115: 1476-1482 [PMID: 9834275 DOI: 10.1016/S0016-5085(98)70026-5]
80. Uchida A, Yamada T, Hayakawa T, Hoshino M. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol 1997; 272: G1249-G1257 [PMID: 9176237]
81. Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal antiinflammatory drugs. Am J Physiol Gastrointest Liver Physiol 2010; 298: G722-G731 [PMID: 20203063 DOI: 10.1152/ajpgi. 00387.2009]
82. Dial EJ, Darling RL, Lichtenberger LM. Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury. J Gastroenterol Hepatol 2008; 23: e384-e389 [PMID: 18086111 DOI: 10.1111/j.1440-1746.2007.05266.x]
83. Yamada T, Hoshino M, Hayakawa T, Kamiya Y, Ohhara H, Mizuno K, Yamada H, Nakazawa T, Inagaki T, Uchida A, Miyaji M, Takeuchi T. Bile secretion in rats with indomethacin-induced intestinal inflammation. Am J Physiol 1996; 270: G804-G812 [PMID: 8967492]
84. Boelsterli UA, Ramirez-Alcantara V. NSAID acyl glucuronides and enteropathy. Curr Drug Metab 2011; 12: 245-252 [PMID: 21395536 DOI: 10.2174/138920011795101877]
85. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 2012; 341: 447-454 [PMID: 22328575 DOI: 10.1124/jpet.111.191122]
86. Atchison CR, West AB, Balakumaran A, Hargus SJ, Pohl LR, Daiker DH, Aronson JF, Hoffmann WE, Shipp BK, Treinen-Moslen M. Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 2000; 119: 1537-1547 [PMID: 11113075 DOI: 10.1053/gast.2000.20186]
87. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977; 14: 333-341 [PMID: 331401 DOI: 10.1016/0090-6980(77)90178-2]
88. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996; 40: 553-560 [PMID: 8887349]
89. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969; 54: 237-249 [PMID: 5765565]
90. Dalby AB, Frank DN, St Amand AL, Bendele AM, Pace NR. Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl Environ Microbiol 2006; 72: 6707-6715 [PMID: 17021222 DOI: 10.1128/AEM.00378-06]
91. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest 2004; 51: 43-51 [PMID: 15000255 DOI: 10.2152/jmi.51.43]
92. Kato N, Mashita Y, Kato S, Mitsufuji S, Yoshikawa T, Takeuchi K. Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO/cGMP-dependent mechanism. Dig Dis Sci 2009; 54: 2346-2356 [PMID: 19101800 DOI: 10.1007/ s10620-008-0646-7]
93. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal antiinflammatory drug-induced small intestinal damage is Tolllike receptor 4 dependent. Gut 2008; 57: 181-187 [PMID: 17639086 DOI: 10.1136/gut.2007.125963]
94. Koga H, Aoyagi K, Matsumoto T, Iida M, Fujishima M. Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am J Physiol 1999; 276: G576-G582 [PMID: 10070032]
95. Kinouchi T, Kataoka K, Bing SR, Nakayama H, Uejima M, Shimono K, Kuwahara T, Akimoto S, Hiraoka I, Ohnishi Y. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol Immunol 1998; 42: 347-355 [PMID: 9654366]
96. Syer SD, McKnight W, Aucouturier A, Martin R, Langella P, Wallace JL. Bifidobacteria exert a protective effect against NSAID-induced enteropathy that is dependent on lactate production. Gastroenterology 2012; 142: S-489
97. Elliott SN, Buret A, McKnight W, Miller MJ, Wallace JL. Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol 1998; 275: G425-G432 [PMID: 9724253]
98. Elliott SN, Wallace JL, McKnight W, Gall DG, Hardin JA, Olson M, Buret A. Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am J Physiol Gastrointest Liver Physiol 2000; 278: G105-G112 [PMID: 10644568]
99. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-662 [PMID: 7906675 DOI: 10.1007/BF00920471]
100. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990; 259: G462-G467 [PMID: 2169206]
101. McCafferty DM, Granger DN, Wallace JL. Indomethacininduced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109: 1173-1180 [PMID: 7557083 DOI: 10.1016/0016-5085(95)90576-6]
102. Chmaisse HM, Antoon JS, Kvietys PR, Grisham MB, Perry MA. Role of leukocytes in indomethacin-induced small bowel injury in the rat. Am J Physiol 1994; 266: G239-G246 [PMID: 8141297]
103. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999; 40: 517-524 [PMID: 10660951 DOI: 10.1006/phrs.1999.0550]
104. Miura S, Suematsu M, Tanaka S, Nagata H, Houzawa S, Suzuki M, Kurose I, Serizawa H, Tsuchiya M. Microcirculatory disturbance in indomethacin-induced intestinal ulcer. Am J Physiol 1991; 261: G213-G219 [PMID: 1651657]
105. Santucci L, Fiorucci S, Di Matteo FM, Morelli A. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 1995; 108: 393-401 [PMID: 7530670 DOI: 10.1016/0016-50 85(95)90065-9]
106. Reuter BK, Wallace JL. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNFalpha release. Am J Physiol 1999; 277: G847-G854 [PMID: 10516151]
107. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chaussade S, Chauvelot-Moachon L. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998; 124: 1385-1394 [PMID: 9723949 DOI: 10.1038/sj.bjp.0701968]
108. Gadelle D, Raibaud P, Sacquet E. beta-Glucuronidase activities of intestinal bacteria determined both in vitro and in vivo in gnotobiotic rats. Appl Environ Microbiol 1985; 49: 682-685 [PMID: 3994372]
109. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis Rheum 1994; 37: 1146-1150 [PMID: 7914409 DOI: 10.1002/art.1780370806]
110. Morris AJ, Murray L, Sturrock RD, Madhok R, Capell HA, Mackenzie JF. Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther 1994; 8: 343-346 [PMID: 7918931 DOI: 10.1111/j.1365-2036.1994. tb00298.x]
111. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009; 69: 1339-1346 [PMID: 19243767 DOI: 10.1016/ j.gie.2008.08.017]
112. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993; 38: 417-425 [PMID: 8444070 DOI: 10.1007/BF01316493]
113. Jenkins RT, Rooney PJ, Hunt RH. Increased bowel permeability to 51Cr-EDTA in controls caused by naproxen is not prevented by cytoprotection. Arthritis Rheum 1998; 31 (Suppl 1): R11
114. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34: 407-411 [PMID: 2493366 DOI: 10.1007/BF01536263]
115. Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A, Gasbarrini G. Clinical trial: the effects of a probiotic mixture on non-steroidal antiinflammatory drug enteropathy-a randomized, doubleblind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 209-214 [PMID: 20384610 DOI: 10.1111/ j.1365-2036.2010.04324.x]
116. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, Tokoro C, Inamori M, Abe Y, Nakajima A. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011; 46: 894-905 [PMID: 21556830 DOI: 10.1007/ s00535-011-0410-1]
117. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Higuchi K, Takeuchi K, Arakawa T. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297: G506-G513 [PMID: 19589943 DOI: 10.1152/ajpgi.90553.2008]
118. Dial EJ, Dohrman AJ, Romero JJ, Lichtenberger LM. Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J Pharm Pharmacol 2005; 57: 93-99 [PMID: 15651117 DOI: 10.1211/0022357055191]
119. Liepke C, Adermann K, Raida M, Mägert HJ, Forssmann WG, Zucht HD. Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem 2002; 269: 712-718 [PMID: 11856332 DOI: 10.1046/j.0014-2956.2001.02712.x]
120. Troost FJ, Saris WH, Brummer RJ. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003; 57: 1579-1585 [PMID: 14647223 DOI: 10.1038/sj.ejcn.1601727]
121. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K. Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci 1995; 40: 2469-2472 [PMID: 7587834 DOI: 10.1007/BF02063257]
122. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 2001; 16: 1112-1119 [PMID: 11686837 DOI: 10.1046/ j.1440-1746.2001.02592.x]
123. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H. Efficacy of rebamipide for diclofenacinduced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebocontrolled, cross-over study. J Gastroenterol 2008; 43: 270-276 [PMID: 18458842 DOI: 10.1007/s00535-007-2155-4]
124. Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a doubleblind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011; 46: 57-64 [PMID: 20924615 DOI: 10.1007/s00535-010-0332-3]
125. Yasuda M, Kawahara R, Hashimura H, Yamanaka N, Iimori M, Amagase K, Kato S, Takeuchi K. Dopamine D-receptor antagonists ameliorate indomethacin-induced small intestinal ulceration in mice by activating α7 nicotinic acetylcholine receptors. J Pharmacol Sci 2011; 116: 274-282 [PMID: 21691039 DOI: 10.1254/jphs.11037FP]
126. Kawahara R, Yasuda M, Hashimura H, Amagase K, Kato S, Takeuchi K. Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice. Eur J Pharmacol 2011; 650: 411-417 [PMID: 20969854 DOI: 10.1016/j.ejphar.2010.10.031]
127. Kato S, Matsuda N, Matsumoto K, Wada M, Onimaru N, Yasuda M, Amagase K, Horie S, Takeuchi K. Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: pro-ulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors. Pharmacol Res 2012; 66: 226-234 [PMID: 22699012 DOI: 10.1016/j.phrs.2012.06.002]
128. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008; 7: 255-270 [PMID: 18219308 DOI: 10.1038/nrd2468]
129. Qandil AM. Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review. Int J Mol Sci 2012; 13: 17244-17274 [PMID: 23247285 DOI: 10.3390/ijms131217244]
130. Whittle BJ, Hansen D, Salmon JA. Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate. Eur J Pharmacol 1985; 116: 153-157 [PMID: 3932082 DOI: 10.1016/0 014-2999(85)90196-7]
131. Wallace JL, McKnight GW. Characterization of a simple animal model for nonsteroidal anti-inflammatory drug induced antral ulcer. Can J Physiol Pharmacol 1993; 71: 447-452 [PMID: 8242479 DOI: 10.1139/y93-066]
132. Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ulcer perforation associated with the use of injectable ketorolac. Ann Pharmacother 1993; 27: 42-43 [PMID: 8431619]
133. Available from: URL: http: //www.logicaltx.com/productpipeline/ nsaid-prodrug.php
134. Goldstein JL, Jungwirthová A, David J, Spindel E, Bouchner L, Pešek F, Searle S, Skopek J, Grim J, Ulč I, Sewell KL. Clinical trial: endoscopic evaluation of naproxen etemesil, a naproxen prodrug, vs. naproxen-a proof-of-concept, randomized, double-blind, active-comparator study. Aliment Pharmacol Ther 2010; 32: 1091-1101 [PMID: 20804454 DOI: 10.1111/j.1365-2036.2010.04442.x]
135. Graham DY. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 2009; 7: 1147-1150 [PMID: 19559818 DOI: 10.1016/j.cgh.2009.06.006]
136. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med 1984; 77: 19-24 [PMID: 6465160 DOI: 10.1016/S0002-9343(84)80014-5]
137. Graham DY, Smith JL, Holmes GI, Davies RO. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985; 38: 65-70 [PMID: 3874038 DOI: 10.1038/clpt.1985.136]
138. Carson JL, Strom BL, Morse ML, West SL, Soper KA, Stolley PD, Jones JK. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147: 1054-1059 [PMID: 3496062]
139. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, Cohen SB, Fleischmann RM. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-2571 [PMID: 8239849 DOI: 10.1001/archinte.1993.00410220073008]
140. Chan FK, Sung JJ, Ching JY, Wu JC, Lee YT, Leung WK, Hui Y, Chan LY, Lai AC, Chung SC. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001; 15: 19-24 [PMID: 11136274 DOI: 10.1046/ j.1365-2036.2001.00890.x]
141. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-1088 [PMID: 8405852]
142. Wallace JL, Ferraz JG. New pharmacologic therapies in gastrointestinal disease. Gastroenterol Clin North Am 2010; 39: 709-720 [PMID: 20951926 DOI: 10.1016/j.gtc.2010.08.020]
143. Wallace JL, Del Soldato P. The therapeutic potential of NONSAIDs. Fundam Clin Pharmacol 2003; 17: 11-20 [PMID: 12588626 DOI: 10.1046/j.1472-8206.2003.00125.x]
144. Caliendo G, Cirino G, Santagada V, Wallace JL. Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem 2010; 53: 6275-6286 [PMID: 20462257 DOI: 10.1021/ jm901638j]
145. Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 2007; 28: 501-505 [PMID: 17884186 DOI: 10.1016/j.tips.2007.09.003]
146. Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006; 131: 259-271 [PMID: 16831608 DOI: 10.1053/j.gastro.2006.02.033]
147. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000; 119: 512-520 [PMID: 10930387 DOI: 10.1053/gast.2000.9304]
148. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi S, Zanardo R, Renga B, Di Sante M, Morelli A, Cirino G, Wallace JL. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 2005; 129: 1210-1224 [PMID: 16230075 DOI: 10.1053/j.gastro.2005.07.060]
149. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118-2120 [PMID: 16912151 DOI: 10.1096/fj.06-6270fje]
150. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-530 [PMID: 7615202 DOI: 10.1016/0016-5085(95)90341-0]
151. Wallace JL. Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxid Redox Signal 2010; 12: 1125-1133 [PMID: 19769457 DOI: 10.1089/ ars.2009.2900]
152. Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov 2002; 1: 375-382 [PMID: 12120413 DOI: 10.1038/nrd794]
153. Konturek SJ, Brzozowski T, Majka J, Pytko-Polonczyk J, Stachura J. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 1993; 239: 215-217 [PMID: 7693490 DOI: 10.1016/0014-2999(93)90997-V]
154. Ma L, Wallace JL. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol 2000; 279: G341-G346 [PMID: 10915643]
155. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132: 261-271 [PMID: 17241876 DOI: 10.1053/j.gastro.2006.11.042]
156. Whittle BJ, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99: 607-611 [PMID: 2110019 DOI: 10.1111/j.1476-5381.1990.tb12977.x]
157. MacNaughton WK, Cirino G, Wallace JL. Endotheliumderived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 1989; 45: 1869-1876 [PMID: 2513461 DOI: 10.1016/0024-3205(89)90540-7]
158. Wallace JL, Dicay M, McKnight W, Martin GR. Hydrogen sulfide enhances ulcer healing in rats. FASEB J 2007; 21: 4070-4076 [PMID: 17634391 DOI: 10.1096/fj.07-8669com]
159. Reuter BK, Cirino G, Wallace JL. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994; 55: PL1-PL8 [PMID: 8015340 DOI: 10.1016/0024-3205(94)90083-3]
160. Davies NM, Røseth AG, Appleyard CB, McKnight W, Del Soldato P, Calignano A, Cirino G, Wallace JL. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997; 11: 69-79 [PMID: 9042976 DOI: 10.1046/j.1365-2036.1997.115286000.x]
161. Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlsson P, Bjarnason IT. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003; 52: 1537-1542 [PMID: 14570719 DOI: 10.1136/gut.52.11.1537]
162. Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Semin Arthritis Rheum 2011; 40: 285-297 [PMID: 20828790 DOI: 10.1016/ j.semarthrit.2010.06.002]
163. Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009; 36: 1290-1297 [PMID: 19411388 DOI: 10.3899/jrheum.081011]
164. Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010; 62: 3635-3644 [PMID: 20722026 DOI: 10.1002/art.27694]
165. Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage 2010; 18: 629-639 [PMID: 20202489 DOI: 10.1016/j.joca.2009.12.013]
166. Wallace JL, Viappiani S, Bolla M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 2009; 30: 112-117 [PMID: 19230986 DOI: 10.1016/ j.tips.2009.01.001]
167. Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L, Kalla A, Genti G, Szechinski J, Ramos-Remus C. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005; 64: 449-456 [PMID: 15345500 DOI: 10.1136/ard.2004.023572]
168. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007; 42: 706-719 [PMID: 17291994 DOI: 10.1016/j.freeradbiomed.2006.12.011]
169. Sparatore A, Perrino E, Tazzari V, Giustarini D, Rossi R, Rossoni G, Erdmann K, Schröder H, Del Soldato P. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic Biol Med 2009; 46: 586-592 [PMID: 19100325 DOI: 10.1016/j.freeradbiomed.2008.11.013]
170. Li L, Bhatia M, Moore PK. Hydrogen sulphide--a novel mediator of inflammation? Curr Opin Pharmacol 2006; 6: 125-129 [PMID: 16487749 DOI: 10.1016/j.coph.2005.10.007]
171. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond) 2011; 121: 459-488 [PMID: 21843150 DOI: 10.1042/CS20110267]
172. Dufton N, Natividad J, Verdu EF, Wallace JL. Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Sci Rep 2012; 2: 499 [PMID: 22787557 DOI: 10.1038/srep00499]
173. Wallace JL, Vong L, McKnight W, Dicay M, Martin GR. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009; 137: 569-578 [PMID: 19375422 DOI: 10.1053/j.gastro.2009.04.012]
174. Wallace JL, Ferraz JG, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal 2012; 17: 58-67 [PMID: 22017247 DOI: 10.1089/ars.2011.4351]
175. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 2012; 7: e35196 [PMID: 22496907 DOI: 10.1371/journal.pone.0035196]
176. Waldram A, Holmes E, Wang Y, Rantalainen M, Wilson ID, Tuohy KM, McCartney AL, Gibson GR, Nicholson JK. Topdown systems biology modeling of host metabotype-microbiome associations in obese rodents. J Proteome Res 2009; 8: 2361-2375 [PMID: 19275195 DOI: 10.1021/pr8009885]
177. Kodela R, Chattopadhyay M, Kashfi K. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. ACS Med Chem Lett 2012; 3: 257-262 [PMID: 22916316 DOI: 10.1021/ ml300002m]
178. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006; 58: 1421-1428 [PMID: 17132203 DOI: 10.1211/jpp.58.10.0001]
179. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, Barreto JC. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1: 154-158 [PMID: 7585013 DOI: 10.1038/nm0295-154]
180. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009; 45: 877-890 [PMID: 20135022]
181. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011; 106: 272-277 [PMID: 21081908 DOI: 10.1038/ajg.2010.436]
182. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008; 28: 431-442 [PMID: 18549459 DOI: 10.1111/ j.1365-2036.2008.03765.x]